Division of Gastroenterology, Department of Internal Medicine, Gachon University, Gil Medical Center, Incheon, Korea.
J Korean Med Sci. 2013 Aug;28(8):1213-9. doi: 10.3346/jkms.2013.28.8.1213. Epub 2013 Jul 31.
rs1127354, rs7270101) gene cause ITPA deficiency and protect against the hemolytic toxicity of ribavirin. We investigated the clinical significance of ITPA variants in Korean patients treated with pegylated interferon (PEG-IFN) plus ribavirin. Of the 133 patients, 108 were CC and 25 were non-CC at rs1127354 (groups A and B, respectively). On the other hand, at rs7270101 all 133 were AA. The mean values of Hemoglobin (Hgb) after 4, 8, and 12 weeks of treatment in groups A and B were 12.2 and 14.0, 11.8 and 13.2, and 11.5 and 12.9, respectively (P=0.001, 0.036, 0.036). Sustained virologic response (SVR) was achieved in 67.8% (40/59) of genotype 1 patients and in 75% (27/36) of non-genotype 1 patients. Regarding ITPA variants, SVR was achieved by 66% and 80% of genotype 1 (P=0.282), and by 78% and 71% (P=0.726) of non-genotype 1. SVR was not significantly different in groups A and B. In conclusion, non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, ITPA genotype is not associated with SVR.
rs1127354、rs7270101) 基因导致 ITPA 缺乏,并能预防利巴韦林的溶血毒性。我们研究了 ITPA 变异在接受聚乙二醇干扰素(PEG-IFN)加利巴韦林治疗的韩国患者中的临床意义。在 133 例患者中,rs1127354 有 108 例为 CC,25 例为非 CC(分别为组 A 和组 B)。另一方面,rs7270101 所有 133 例均为 AA。组 A 和组 B 中治疗 4、8 和 12 周后血红蛋白(Hgb)的平均值分别为 12.2 和 14.0、11.8 和 13.2、11.5 和 12.9(P=0.001、0.036、0.036)。基因型 1 患者中 67.8%(40/59)和非基因型 1 患者中 75%(27/36)获得持续病毒学应答(SVR)。关于 ITPA 变异,基因型 1 患者中 SVR 的获得率为 66%和 80%(P=0.282),非基因型 1 患者中为 78%和 71%(P=0.726)。组 A 和组 B 之间的 SVR 无显著差异。总之,rs1127354 非 CC 且不涉及 rs7270101 与利巴韦林引起的贫血保护密切相关,但 ITPA 基因型与 SVR 无关。